Gemmer Asset Management LLC grew its position in shares of Pfizer, Inc. (NYSE:PFE) by 84.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,771 shares of the biopharmaceutical company’s stock after purchasing an additional 11,763 shares during the period. Gemmer Asset Management LLC’s holdings in Pfizer were worth $866,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. St. Johns Investment Management Company LLC lifted its stake in Pfizer by 6.2% during the second quarter. St. Johns Investment Management Company LLC now owns 37,058 shares of the biopharmaceutical company’s stock worth $1,245,000 after purchasing an additional 2,166 shares in the last quarter. Edmp Inc. lifted its stake in Pfizer by 0.6% during the second quarter. Edmp Inc. now owns 105,023 shares of the biopharmaceutical company’s stock worth $3,528,000 after purchasing an additional 580 shares in the last quarter. Nadler Financial Group Inc. lifted its stake in Pfizer by 4.4% during the second quarter. Nadler Financial Group Inc. now owns 33,120 shares of the biopharmaceutical company’s stock worth $1,113,000 after purchasing an additional 1,381 shares in the last quarter. Howe & Rusling Inc. lifted its stake in Pfizer by 1.8% during the second quarter. Howe & Rusling Inc. now owns 369,928 shares of the biopharmaceutical company’s stock worth $12,426,000 after purchasing an additional 6,427 shares in the last quarter. Finally, Leavell Investment Management Inc. lifted its stake in Pfizer by 1.5% during the second quarter. Leavell Investment Management Inc. now owns 138,331 shares of the biopharmaceutical company’s stock worth $4,647,000 after purchasing an additional 2,018 shares in the last quarter. Institutional investors own 68.99% of the company’s stock.

In related news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock valued at $15,813,961 in the last three months. Insiders own 0.06% of the company’s stock.

A number of research firms have commented on PFE. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Friday. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Tuesday, October 3rd. Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Sanford C. Bernstein set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, September 19th. Finally, Jefferies Group LLC set a $37.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Monday, September 18th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $38.21.

Shares of Pfizer, Inc. (NYSE PFE) traded up 0.014% during trading on Monday, hitting $36.055. The company’s stock had a trading volume of 3,641,963 shares. The firm’s 50 day moving average price is $34.72 and its 200-day moving average price is $33.69. The company has a market cap of $214.43 billion, a PE ratio of 26.375 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.24.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 EPS. On average, analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.55%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is currently 94.12%.

ILLEGAL ACTIVITY WARNING: “Gemmer Asset Management LLC Grows Holdings in Pfizer, Inc. (PFE)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/09/gemmer-asset-management-llc-grows-holdings-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.